Arvinas

Vepdegestrant must become the first commercial proof point that Arvinas' PROTAC approach can produce a differentiated, approvable medicine rather than only collaboration revenue and clinical optionality. If it holds, Arvinas gains a regulatory and commercial anchor for the platform; if it breaks, the market will likely discount the rest of the pipeline much more heavily.

The PROTAC Discovery Engine has to keep producing multiple clinically credible assets, so Arvinas is valued as a repeatable modality company rather than a one-product breast-cancer story. Repeatability creates portfolio value and partnership leverage; failure would leave shareholders exposed to a single regulatory and commercial outcome.

ARV-102 must show that oral PROTAC degraders can safely reach and engage central nervous system targets, expanding Arvinas beyond oncology into harder-to-drug neurodegenerative diseases. CNS validation would materially widen the platform's addressable market; failure would narrow the perceived platform to oncology and reduce upside optionality.

Arvinas' partnered model has to replace the scale it lacks: Pfizer and any selected third-party commercial partner must execute vepdegestrant development and launch while preserving Arvinas' economics and cash runway. Good partner execution lets a 246-employee clinical biotech access global development and commercialization capabilities; poor execution leaves Arvinas under-resourced at the exact point value should be realized.

If approved, Arvinas' product candidates must demonstrate enough safety, efficacy or convenience advantage to earn premium pricing despite generics, payor pressure and better-funded competitors. Clinical success alone is not enough; durable shareholder value requires reimbursement and market adoption that justify the cost of development.